Abstract：
Chronic hemodialysis patients exhibit an excessive cardiovascular risk and a marked increase in both thromboembolism and bleeding episodes. Factor XI inhibition may provide anticoagulation, with a low risk of bleeding, and several factor XI inhibitors, including fesomersen, an antisense oligonucleotide, are under development. Recently, a phase 2 study of fesomersen showed a good safety profile in chronic hemodialysis patients and suggested that clotting rates of the arteriovenous fistula and the dialysis circuit are lower.
摘要：
慢性血液透析患者表现出过度的心血管风险，并且血栓栓塞和出血事件均显着增加。因子XI抑制可以提供抗凝，出血风险低，和几种XI因子抑制剂，包括Fesomersen,反义寡核苷酸，正在开发中。最近,fesomersen的一项2期研究显示，慢性血液透析患者的安全性良好，并提示动静脉瘘和透析回路的凝血率较低。
